Navigation Links
Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Date:4/23/2008

EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that Dr. Jie Lu and Dr. Zhengping Zhuang of the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and its collaborator, Lixte Biotechnology Holdings. Inc., reported at the Annual Meeting of the American Association of Cancer Research that its lead compound LB-1, one of a patent-pending proprietary series of agents, has anti-cancer activity against human glioblastoma multiforme cells in a mouse model of cancer. Glioblastoma multiforme is the most common and aggressive brain tumor of adults.

The Dr. John S. Kovach, President and CEO of Lixte, said that the company and SNB, NINDS are continuing to develop LB-1 and analogs of the compound for the treatment of human brain cancers. Brain cancers pose a particular challenge to the development of effective drug treatments. The brain is protected by a physiological barrier that prevents the entry of many compounds from the blood into brain tissue. To be effective, drugs must be designed either to pass this barrier or be administered directly into the brain. "We are pursuing both strategies for the treatment of glioblastoma multiforme in a rat model in which the cancer is growing in the brain," said Dr. Kovach. "We want to be certain that we achieve drug delivery into the brain at concentrations that inhibit these tumors."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):

NINDS (http://www.ninds.nih.gov) is a component of
'/>"/>

SOURCE Lixte Biotechnology Holdings
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 North America Gynecological Devices ... GlobalData,s new report, "North America Gynecological ... data on the North America Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... significant growth during the last decade due ... environment, natural calamities and technological advancements. This ... strategies within various segments of the ambulance ... as transportation equipment, blood and hemorrhage control ...
(Date:9/17/2014)... 17, 2014  Decision Resources Group finds ... eligible for biologic therapy, only a proportion ... gastroenterologists cite patients, discomfort with biological therapy ... rates, followed by cost-related issues and payer ... biologics, Janssen Biotech,s Remicade and AbbVie,s Humira ...
Breaking Medicine Technology:North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... 2012  Sensitech Inc., the global leader in cold ... Transport Association (IATA) has deemed Sensitech,s full range ... in compliance with the 53rd edition of the ... published by the United Nations.   The size and ...
... FRANCISCO, April 26, 2012 Onyx Pharmaceuticals, Inc. (Nasdaq: ... Food and Drug Administration,s (FDA) Oncologic Drugs Advisory Committee ... for carfilzomib for the treatment of patients with relapsed ... two prior therapies. ODAC will review carfilzomib at its ...
Cached Medicine Technology:Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA 2Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma 2Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma 3
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... 18, 2014 The global ablation technologies ... 9.6% from 2014 to 2019. Although mature markets (such ... larger shares in the ablation technologies market in 2014, ... highest CAGR of 12.8% in the next five years.Factors ... infrastructure, growing number of hospitals and surgical centers, and ...
(Date:9/17/2014)... 18, 2014 iFitDress.com, a renowned wedding dress ... petite evening dresses . All these outfits are now ... discounted shipping costs. , “iFitDress.com is a professional company ... We are now busy selling our new collection of petite ... an order above $800 can get free shipping. All these ...
(Date:9/17/2014)... 2014 Mercy College is proud to welcome ... of Social and Behavioral Sciences. As dean, she ... the academic mission of the dynamic undergraduate and graduate programs ... honored to join Mercy College. During my first three ... campuses dedicated to the educational mission of the College. ...
(Date:9/17/2014)... Lake City, UT (PRWEB) September 17, 2014 ... Miss America 2015 Kira Kazantsev and ushered in ... need charitable support. As Miss America Organization’s official ... is welcoming Kazantsev as its newest National Goodwill ... her at member Children’s Miracle Network Hospitals across ...
Breaking Medicine News(10 mins):Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Elegant Petite Evening Dresses Introduced By Renowned Supplier iFitDress.com 2Health News:Mercy College Welcomes New Dean of the School of Social and Behavioral Sciences 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3
... Sept. 20 Approximately 100,corporate pilots and ... earn,lifesaving certifications provided by the American Heart ... Safety Standdown in Wichita, Kan.,Oct. 22-25. ... event offers safety,training to the business aviation ...
... single dose of Otsukas investigational oral medication tolvaptan, ... in hemodynamics associated with a significant increase in ... (ADHF) who participated in the international trial the ... with HEart failure (ECLIPSE), presented at the late ...
... Inc.,(TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing ... technologies for,the management of cancer, today announced that ... Vincent were elected to the Board of Directors ... 19, 2007. Dr. Burger has been,unanimously elected as ...
... A Florida pharmacy,owner and a Kentucky physician pleaded ... pharmacy business that generated more than,$126 million in ... Assistant Attorney General Alice S. Fisher of the ... the Southern District of,California announced today. Claude ...
... ... Zoo, Chicago, FAIRFAX, Va., Sept. 19 ... heavy vaginal,bleeding caused by uterine fibroids, noncancerous tumors that develop in,the muscular ... of Chicago, IL, and is a 46-year-old menopausal western lowland,gorilla. Doctors have ...
... Event to Take Place Friday February 8th, 2008, ... Inc. of Rancho Mirage, will host its first,annual Gala, ... A. Lopez, Director of Internal Medicine Specialists-Rancho,Mirage. The elegant ... Resort in Rancho Mirage and will begin at 6:00 ...
Cached Medicine News:Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 2Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 3Health News:ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan 2Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 2Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 3Health News:Lorus Therapeutics announces election of three new Directors and appoints a new Chairman 4Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 2Health News:Doctor and Pharmacy Owner Plead Guilty in Internet Pharmacy Conspiracy 3Health News:Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists 2Health News:Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists 3Health News:IMA South American Extravaganza Dinner to Honor Coachella Valley Doctor 2
... high-end microplate reader with outstanding sensitivity and ... Fluorescence Intensity - FRET , Fluorescence Polarization ... , Luminescence , , , ... reader with fastest read times. The ultimate ...
GENios Pro, TECANs advanced, multi-functional injector reader offers simultaneous reagent dispensing and detection for monitoring of fast kinetic reactions...
... Throughput Screening (UHTS), Analyst GT delivers ... for smooth transfer of assays into ... all the detection modalities of Analyst ... polarization, time-resolved fluorescence, luminescence, absorbance, as ...
... a fully automated microplate based multi-detection ... principles:, , Fluorescence Polarization , ... , High-Performance Luminescence (flash and glow) ... is designed for the widest possible ...
Medicine Products: